Q3 2023 Torrent Pharmaceuticals Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Torrent Pharmaceuticals Q3 FY '23 Earnings Conference Call. (Operator Instructions)
I now hand the conference over to Mr. Sudhir Menon.
Thank you. Good evening, and welcome to quarter 3 FY '23 earnings call. Quarter 3 registered revenue growth of 18%, led by strong growth in the branded generic markets and steady performance of the generic markets. Branded generic markets constituted 70% of the total revenue base. The growth in the branded generic markets were primarily driven by new launch momentum, performance of the top brands and integration of acquired portfolio.
In terms of financial performance during the quarter, the revenues were INR 2,491 crores, up by 18% on Y-o-Y basis. Operating EBITDA was INR 724 crores with operating EBITDA margins at 29.1%. There is a one-off impact on gross margins by around 0.6% for the quarter due to under absorption of manufacturing cost as there was a temporary
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
